A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus

Schulze, Kai; Staib, Caroline; Schätzl, Hermann; Ebensen, Thomas; Erfle, Volker; Guzmán, Carlos A.

doi:10.1016/j.vaccine.2008.09.006

Cited by 24 publications

(21 citation statements)

References 40 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yet, optimal boosting required antigen administration via the IM route. Our results confirm earlier results from studies on influenza, HSV, HIV-1, and SARS, which all found that IN priming, whether given by protein, DNA or recombinant virus vaccines, should be followed by IM boost for induction of optimal serum antibody responses [21,23,24,33]. For IPLprimed mice, IM and IPL boosting were equally effective in eliciting serum IgG and HAI titers.…”

Section: Discussionsupporting

confidence: 89%

“…In addition to the magnitude, the phenotype of an immune response also determines the effectiveness of its protection against invading pathogens. A Th1 type immune response, characterized by IgG2a and IFN-γ production in mice, has been shown to correlate positively with improved protection against influenza virus [13,30] [21,23,24,33]. As for IPL immunization, GPI-0100-adjuvanted influenza vaccine elicited marginal IgG2a and IFN-γ responses using IPL/IPL approach.…”

Section: Discussionmentioning

confidence: 99%

“…A potential way to combine the advantages of mucosal and systemic immunization involves prime-boost strategies with mucosal priming and systemic boosting or vice-versa. Several studies have investigated such strategies, but the majority of these make use of DNA vaccines and/or recombinant virus vaccines during priming, boosting or both [16][17][18][19][20][21][22][23][24][25][26]. So far, little is known about prime-boost strategies for optimization of mucosal and systemic immune responses to protein-based influenza vaccines.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of Mucosal and Systemic Immune Responses Elicited by GPI-0100- Adjuvanted Influenza Vaccine Delivered by Different Immunization Strategies

et al. 2013

View full text Add to dashboard Cite

Vaccines for protection against respiratory infections should optimally induce a mucosal immune response in the respiratory tract in addition to a systemic immune response. However, current parenteral immunization modalities generally fail to induce mucosal immunity, while mucosal vaccine delivery often results in poor systemic immunity. In order to find an immunization strategy which satisfies the need for induction of both mucosal and systemic immunity, we compared local and systemic immune responses elicited by two mucosal immunizations, given either by the intranasal (IN) or the intrapulmonary (IPL) route, with responses elicited by a mucosal prime followed by a systemic boost immunization. The study was conducted in BALB/c mice and the vaccine formulation was an influenza subunit vaccine supplemented with GPI-0100, a saponin-derived adjuvant. While optimal mucosal antibody titers were obtained after two intrapulmonary vaccinations, optimal systemic antibody responses were achieved by intranasal prime followed by intramuscular boost. The latter strategy also resulted in the best T cell response, yet, it was ineffective in inducing nose or lung IgA. Successful induction of secretory IgA, IgG and T cell responses was only achieved with prime-boost strategies involving intrapulmonary immunization and was optimal when both immunizations were given via the intrapulmonary route. Our results underline that immunization via the lungs is particularly effective for priming as well as boosting of local and systemic immune responses.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Mucosal and Systemic Immune Responses Elicited by GPI-0100- Adjuvanted Influenza Vaccine Delivered by Different Immunization Strategies

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Thus, different strategies have been developed to increase immunogenicity, including the use of mucosal adjuvants (30,31). BPPcysMPEG was proven to be an efficient compound for promoting immune responses at the systemic and mucosal levels when coadministered with a vaccine antigen (23,(32)(33)(34). Sufficient experimental evidence supports the ability of pcDNA-SOD, a plasmid containing the Brucella Cu,Zn SOD-encoding gene, to promote immune protection in mice (19,35) and SOD-specific immune responses in cattle (20) following vaccination.…”

Section: Discussionmentioning

confidence: 99%

Use ofS-[2,3-Bispalmitoyiloxy-(2R)-Propyl]-R-Cysteinyl-Amido-Monomethoxy Polyethylene Glycol as an Adjuvant Improved Protective Immunity Associated with a DNA Vaccine Encoding Cu,Zn Superoxide Dismutase of Brucella abortus in Mice

Retamal-Díaz

Riquelme-Neira

Sáez

et al. 2014

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

“…14 Furthermore, N protein is abundantly shed during SARS infection and N protein specific antibodies and memory T cells can be detected in SARS-recovered patients. 15,16 A number of studies have used recombinant N protein 17,18 or DNA encoding N protein [19][20][21] as vaccine antigen to elicit humoral and cellular immune responses in animal models. In this context, we selected plasmid DNA encoding N protein (pVAXN) as vaccine antigen and chitosan as DNA delivery vehicle.…”

Section: Introductionmentioning

confidence: 99%

Dendritic Cell Targeted Chitosan Nanoparticles for Nasal DNA Immunization against SARS CoV Nucleocapsid Protein

et al. 2012

View full text Add to dashboard Cite

This work investigates the formulation and in vivo efficacy of dendritic cell (DC) targeted plasmid DNA loaded biotinylated chitosan nanoparticles for nasal immunization against nucleocapsid (N) protein of severe acute respiratory syndrome coronavirus (SARS-CoV) as antigen. The induction of antigen-specific mucosal and systemic immune response at the site of virus entry is a major challenge for vaccine design. Here, we designed a strategy for non-invasive receptor mediated gene delivery to nasal resident DCs. The pDNA loaded biotinylated chitosan nanoparticles were prepared using a complex coacervation process and characterized for size, shape, surface charge, plasmid loading and protection against nuclease digestion. The pDNA loaded biotinylated chitosan nanoparticles were targeted with bifunctional fusion protein (bfFp) vector for achieving DC selective targeting. The bfFp is a recombinant fusion protein consisting of truncated core-streptavidin fused with anti-DEC-205 single chain antibody (scFv). The core-streptavidin arm of fusion protein binds with biotinylated nanoparticles, while anti-DEC-205 scFv imparts targeting specificity to DC DEC-205 receptor. We demonstrate that intranasal administration of bfFp targeted formulations along with anti-CD40 DC maturation stimuli enhanced magnitude of mucosal IgA as well as systemic IgG against N protein. The strategy led to the detection of augmented levels of N protein specific systemic IgG and nasal IgA antibodies. However, following intranasal delivery of naked pDNA no mucosal and systemic immune responses were detected. A parallel comparison of targeted formulations using intramuscular and intranasal route showed that the intramuscular route is superior for induction of systemic IgG responses compared with the intranasal route. Our results suggest that targeted pDNA delivery through non-invasive intranasal route can be a strategy for designing low-dose vaccines.

show abstract

A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus

Cited by 24 publications

References 40 publications

Evaluation of Mucosal and Systemic Immune Responses Elicited by GPI-0100- Adjuvanted Influenza Vaccine Delivered by Different Immunization Strategies

Evaluation of Mucosal and Systemic Immune Responses Elicited by GPI-0100- Adjuvanted Influenza Vaccine Delivered by Different Immunization Strategies

Use ofS-[2,3-Bispalmitoyiloxy-(2R)-Propyl]-R-Cysteinyl-Amido-Monomethoxy Polyethylene Glycol as an Adjuvant Improved Protective Immunity Associated with a DNA Vaccine Encoding Cu,Zn Superoxide Dismutase of Brucella abortus in Mice

Dendritic Cell Targeted Chitosan Nanoparticles for Nasal DNA Immunization against SARS CoV Nucleocapsid Protein

Contact Info

Product

Resources

About